GRI Bio Inc
GRI
View Detailed Chart
2.390USD
+0.200+9.13%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
42.48KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+9.13%
5 Days
-26.69%
1 Month
-71.36%
6 Months
+91.20%
Year to Date
-65.41%
1 Year
-70.65%
View Detailed Chart
TradingKey Stock Score of GRI Bio Inc
Currency: USD Updated: 2026-02-06Key Insights
GRI Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 207 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is low.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 644.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GRI Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
GRI Bio Inc Highlights
StrengthsRisks
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.80K shares, increasing 40.38% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 607.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
644.000
Target Price
+24293.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
GRI Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GRI Bio Inc Info
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Ticker SymbolGRI
CompanyGRI Bio Inc
CEOHertz (W. Marc)
Websitehttps://www.gribio.com/
Related Instruments
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69205.000
-396.180 (-0.57%)
282.580
+22.390 (+8.61%)
2081.780
-21.040 (-1.00%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
